文献速递肾移植

肾移植受者丙型肝炎病毒感染的直接抗病毒治疗

Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
PubMed 文献 · Kidney Int · 2018-01-09

肾移植受者合并HCV感染与发病率和死亡率增加相关,干扰素α为基础的治疗因可诱发急性排斥而相对禁忌。全口服、无干扰素的直接抗病毒治疗在肾移植受者中有效且耐受良好,近期文献显示418例中406例(97%)被治愈,多数采用索磷布韦为基础方案,且未增加急性排斥率。

要点

  • 直接抗病毒治疗在肾移植受者中治愈HCV达97%(406/418),且耐受良好。
  • 直接抗病毒治疗未增加肾移植受者急性排斥反应的发生率。
  • 已有方案可治疗晚期移植物功能不全(eGFR<30 ml/min/1.73 m2)及泛基因型HCV感染。

核心结论

  • 直接抗病毒治疗可有效治愈肾移植受者的HCV感染,且不增加急性排斥风险。

研究设计与样本

  • 本文为综述,汇总肾移植受者HCV感染的流行病学及直接抗病毒治疗的研究现状。

主要发现

  • 近期文献报告直接抗病毒治疗在418例肾移植受者中治愈406例(97%),多数采用索磷布韦为基础方案。
  • 较小样本的肾移植受者使用paritaprevir-ritonavir、ombitasvir和dasabuvir、elbasvir-grazoprevir或glecaprevir-pibrentasvir治疗也获得良好效果。
  • 直接抗病毒治疗耐受良好,未增加急性排斥反应发生率。

关键数值与推荐

  • 已批准可治疗晚期移植物功能不全(eGFR<30 ml/min/1.73 m2)的方案。
  • 已有泛基因型方案对HCV全部6种主要基因型均有活性。

临床怎么用

  • 肾移植受者合并HCV感染可考虑全口服、无干扰素的直接抗病毒治疗。
  • 选择方案时需考虑移植物功能(eGFR<30 ml/min/1.73 m2可用特定方案)及HCV基因型(泛基因型方案覆盖全部6种主要基因型)。

局限性

  • 本文为综述,未报告原始研究的具体设计细节及样本量等数据。
  • 部分直接抗病毒方案在肾移植受者中的治疗经验样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated with increased morbidity and mortality compared with recipients who do not have chronic HCV infection. Because interferon-α-based therapies can precipitate acute rejection, they are relatively contraindicated after kidney transplantation. Thus, the majority of kidney transplant recipients with HCV remain untreated. There are now all-oral, interferon-free direct-acting antiviral therapies for HCV infection that are extremely effective and well tolerated in the general population. Recent reports in the literature demonstrate that direct-acting antiviral therapies effectively cured HCV in 406 of 418 kidney transplant recipients (97%); the majority were treated with sofosbuvir-based regimens. Smaller numbers of kidney transplant recipients have been treated with paritaprevir-ritonavir, ombitasvir and dasabuvir, elbasvir-grazoprevir, or glecaprevir-pibrentasvir with excellent success. Direct-acting antiviral therapies were well tolerated and did not increase the rate of acute rejection. The latest advances include approval of regimens that can treat patients with advanced allograft dysfunction (eGFR < 30 ml/min per 1.73 m2) and "pan-genotypic" regimens that have activity against all 6 major genotypes of HCV. This review summarizes what is known about the epidemiology of HCV infection in kidney transplant recipients, and presents the landscape of direct-acting antiviral therapies and areas in need of further investigation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Chute DF, Chung RT, Sise ME, et al. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient. Kidney Int. 2018. PMID: 29325996. doi:10.1016/j.kint.2017.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。